Document is current
Any future updates will be listed below
-
Authors
Lee, Su In
Nam, Ah-Rong
Oh, Kyoung-Seok
Kim, Jae-Min
Bang, Ju-Hee
Jeong, Yoojin
Choo, Sea Young
Kim, Hyo Jung
Yoon, Jeesun
Kim, Tae-Yong
Oh, Do-Youn
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2021R1A2C2007430)
- License Information
-
More Information
Article History
Received: 2 January 2025
Accepted: 9 May 2025
First Online: 13 June 2025
Declarations
:
: Oh DY is a consultant or advisory board member of AstraZeneca, Novartis, Genentech/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS/Celgene, BeiGene, Basilea, Turning Point, Yuhan, Arcus Biosciences, IQVIA, MSD, LG Chem, Astellas, Abbvie, J-Pharma, Mirati Therapeutics, Eutilex, Moderna, Idience, Alligator Bioscience AB, Hana pharm. Research grant from AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, and Handok.
